194 related articles for article (PubMed ID: 22270174)
21. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
22. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer.
La TH; Filion EJ; Turnbull BB; Chu JN; Lee P; Nguyen K; Maxim P; Quon A; Graves EE; Loo BW; Le QT
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1335-41. PubMed ID: 19289263
[TBL] [Abstract][Full Text] [Related]
23. FDG PET/CT imaging of oropharyngeal squamous cell carcinoma: characteristics of human papillomavirus-positive and -negative tumors.
Tahari AK; Alluri KC; Quon H; Koch W; Wahl RL; Subramaniam RM
Clin Nucl Med; 2014 Mar; 39(3):225-31. PubMed ID: 24152652
[TBL] [Abstract][Full Text] [Related]
24. Metabolic tumour volume as a prognostic factor for oral cavity squamous cell carcinoma treated with primary surgery.
Zhang H; Seikaly H; Abele JT; Jeffery DT; Harris JR; O'Connell DA
J Otolaryngol Head Neck Surg; 2014 Oct; 43(1):33. PubMed ID: 25312990
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
26. 18F-FDG PET/CT as a semiquantitative imaging marker in HPV-p16-positive oropharyngeal squamous cell cancers.
Huang YT; Ravi Kumar AS; Bhuta S
Nucl Med Commun; 2015 Jan; 36(1):16-20. PubMed ID: 25340950
[TBL] [Abstract][Full Text] [Related]
27. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
Jayachandran P; Pai RK; Quon A; Graves E; Krakow TE; La T; Loo BW; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):471-7. PubMed ID: 22381904
[TBL] [Abstract][Full Text] [Related]
28. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.
Rischin D; Young RJ; Fisher R; Fox SB; Le QT; Peters LJ; Solomon B; Choi J; O'Sullivan B; Kenny LM; McArthur GA
J Clin Oncol; 2010 Sep; 28(27):4142-8. PubMed ID: 20697079
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204
[TBL] [Abstract][Full Text] [Related]
31. 18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers?
Kendi AT; Corey A; Magliocca KR; Nickleach DC; Galt J; Switchenko JM; El-Deiry MW; Wadsworth JT; Hudgins PA; Saba NF; Schuster DM
Eur J Radiol; 2015 Jun; 84(6):1171-6. PubMed ID: 25816993
[TBL] [Abstract][Full Text] [Related]
32. The prognostic role of 18F-fluorodeoxyglucose PET in head and neck cancer depends on HPV status.
Moan JM; Amdal CD; Malinen E; Svestad JG; Bogsrud TV; Dale E
Radiother Oncol; 2019 Nov; 140():54-61. PubMed ID: 31177043
[TBL] [Abstract][Full Text] [Related]
33. Prognostic role of metabolic parameters of (18)F-FDG PET-CT scan performed during radiation therapy in locally advanced head and neck squamous cell carcinoma.
Min M; Lin P; Lee MT; Shon IH; Lin M; Forstner D; Bray V; Chicco A; Tieu MT; Fowler A
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1984-94. PubMed ID: 26081941
[TBL] [Abstract][Full Text] [Related]
34. Changes in cervical cancer FDG uptake during chemoradiation and association with response.
Kidd EA; Thomas M; Siegel BA; Dehdashti F; Grigsby PW
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):116-22. PubMed ID: 22520475
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer.
Chung HH; Kang SY; Ha S; Kim JW; Park NH; Song YS; Cheon GJ
J Gynecol Oncol; 2016 Mar; 27(2):e15. PubMed ID: 26768781
[TBL] [Abstract][Full Text] [Related]
36. Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma.
Abd El-Hafez YG; Moustafa HM; Khalil HF; Liao CT; Yen TC
Oral Oncol; 2013 Mar; 49(3):261-8. PubMed ID: 23036774
[TBL] [Abstract][Full Text] [Related]
37. Textural features of pretreatment 18F-FDG PET/CT images: prognostic significance in patients with advanced T-stage oropharyngeal squamous cell carcinoma.
Cheng NM; Fang YH; Chang JT; Huang CG; Tsan DL; Ng SH; Wang HM; Lin CY; Liao CT; Yen TC
J Nucl Med; 2013 Oct; 54(10):1703-9. PubMed ID: 24042030
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
Liao S; Penney BC; Zhang H; Suzuki K; Pu Y
Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
[TBL] [Abstract][Full Text] [Related]
39. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108
[TBL] [Abstract][Full Text] [Related]
40. FDG-PET/CT Predicts Outcome in Oropharingeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes.
Mapelli P; Broggi S; Incerti E; Alongi P; Kirienko M; Fiorino C; Dell Oca I; Fallanca F; Vanoli EG; Di Muzio NG; Gianolli L; Picchio M
Curr Radiopharm; 2017 Aug; 10(2):102-110. PubMed ID: 28412923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
